295 related articles for article (PubMed ID: 19875936)
1. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.
Pandey A; Singh N; Sambhara S; Mittal SK
Hum Vaccin; 2010 Feb; 6(2):178-88. PubMed ID: 19875936
[TBL] [Abstract][Full Text] [Related]
2. New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges.
Steel J
BioDrugs; 2011 Oct; 25(5):285-98. PubMed ID: 21942913
[TBL] [Abstract][Full Text] [Related]
3. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness.
Tseng YF; Hu AY; Huang ML; Yeh WZ; Weng TC; Chen YS; Chong P; Lee MS
PLoS One; 2011; 6(10):e24057. PubMed ID: 22022351
[TBL] [Abstract][Full Text] [Related]
4. Production of adenovirus vectors and their use as a delivery system for influenza vaccines.
Vemula SV; Mittal SK
Expert Opin Biol Ther; 2010 Oct; 10(10):1469-87. PubMed ID: 20822477
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of novel disposable bioreactors on pandemic influenza virus production.
Lai CC; Weng TC; Tseng YF; Chiang JR; Lee MS; Hu AY
PLoS One; 2019; 14(8):e0220803. PubMed ID: 31404117
[TBL] [Abstract][Full Text] [Related]
6. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
[TBL] [Abstract][Full Text] [Related]
7. A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.
Hoelscher MA; Singh N; Garg S; Jayashankar L; Veguilla V; Pandey A; Matsuoka Y; Katz JM; Donis R; Mittal SK; Sambhara S
J Infect Dis; 2008 Apr; 197(8):1185-8. PubMed ID: 18462165
[TBL] [Abstract][Full Text] [Related]
8. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1.
Zhou F; Zhou J; Ma L; Song S; Zhang X; Li W; Jiang S; Wang Y; Liao G
Biochem Biophys Res Commun; 2012 May; 421(4):850-4. PubMed ID: 22554519
[TBL] [Abstract][Full Text] [Related]
9. Pandemic H5N1 influenza vaccine development: an update.
El Sahly HM; Keitel WA
Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
[TBL] [Abstract][Full Text] [Related]
10. New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.
Hoelscher MA; Jayashankar L; Garg S; Veguilla V; Lu X; Singh N; Katz JM; Mittal SK; Sambhara S
Clin Pharmacol Ther; 2007 Dec; 82(6):665-71. PubMed ID: 17957181
[TBL] [Abstract][Full Text] [Related]
11. Preparing for a possible pandemic: influenza A/H5N1 vaccine development.
Keitel WA; Atmar RL
Curr Opin Pharmacol; 2007 Oct; 7(5):484-90. PubMed ID: 17644429
[TBL] [Abstract][Full Text] [Related]
12. Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines.
Zhang J
Viruses; 2012 Nov; 4(11):2711-35. PubMed ID: 23202501
[TBL] [Abstract][Full Text] [Related]
13. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
Cheng A; Hsieh SM; Pan SC; Li YH; Hsieh EF; Lee HC; Lin TW; Lai KL; Chen C; Shi-Chung Chang S; Chang SC
J Microbiol Immunol Infect; 2019 Oct; 52(5):685-692. PubMed ID: 31255574
[TBL] [Abstract][Full Text] [Related]
14. Development of vaccines against influenza A virus (H5N1).
Li WC; Huang YC
Chang Gung Med J; 2007; 30(4):294-304. PubMed ID: 17939259
[TBL] [Abstract][Full Text] [Related]
15. Cloned cDNA of A/swine/Iowa/15/1930 internal genes as a candidate backbone for reverse genetics vaccine against influenza A viruses.
Lekcharoensuk P; Wiriyarat W; Petcharat N; Lekcharoensuk C; Auewarakul P; Richt JA
Vaccine; 2012 Feb; 30(8):1453-9. PubMed ID: 22230579
[TBL] [Abstract][Full Text] [Related]
16. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.
Mayrhofer J; Coulibaly S; Hessel A; Holzer GW; Schwendinger M; Brühl P; Gerencer M; Crowe BA; Shuo S; Hong W; Tan YJ; Dietrich B; Sabarth N; Savidis-Dacho H; Kistner O; Barrett PN; Falkner FG
J Virol; 2009 May; 83(10):5192-203. PubMed ID: 19279103
[TBL] [Abstract][Full Text] [Related]
17. A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].
Plosker GL
Drugs; 2012 Jul; 72(11):1543-57. PubMed ID: 22788239
[TBL] [Abstract][Full Text] [Related]
18. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production.
Dong J; Matsuoka Y; Maines TR; Swayne DE; O'Neill E; Davis CT; Van-Hoven N; Balish A; Yu HJ; Katz JM; Klimov A; Cox N; Li DX; Wang Y; Guo YJ; Yang WZ; Donis RO; Shu YL
Influenza Other Respir Viruses; 2009 Nov; 3(6):287-95. PubMed ID: 19903211
[TBL] [Abstract][Full Text] [Related]
19. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.
Montomoli E; Khadang B; Piccirella S; Trombetta C; Mennitto E; Manini I; Stanzani V; Lapini G
Expert Rev Vaccines; 2012 May; 11(5):587-94. PubMed ID: 22827244
[TBL] [Abstract][Full Text] [Related]
20. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.
Shoji Y; Chichester JA; Jones M; Manceva SD; Damon E; Mett V; Musiychuk K; Bi H; Farrance C; Shamloul M; Kushnir N; Sharma S; Yusibov V
Hum Vaccin; 2011; 7 Suppl():41-50. PubMed ID: 21266846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
